Effects of long-term pravastatin treatment on serum and urinary monocyte chemoattractant protein-1 levels and renal function in type 2 diabetic patients with normoalbuminuria

Renal Failure

Volumn 29, Issue 7, 2007, Pages 791-796

  Fujita, Hiroki ^a   Koshimura, Jun ^a   Sato, Takehiro ^a   Miura, Takeshi ^a   Sasaki, Hiroshi ^a   Morii, Tsukasa ^a   Narita, Takuma ^a   Kakei, Masafumi ^a   Ito, Seiki ^a   Yamada, Yuichiro ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Low density lipoprotein cholesterol; Monocyte chemoattractant protein 1; Normoalbuminuria; Pravastatin; Type 2 diabetes

Indexed keywords

ACETYLGLUCOSAMINIDASE; ALBUMIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE MARKER; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MALE; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINE LEVEL; VASCULITIS;

AGED; ALBUMINURIA; CHEMOKINE CCL2; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MALE; MIDDLE AGED; PRAVASTATIN;

EID: 36248935639     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701543056     Document Type: Article

References (27)

1. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, et al. Risk factor for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-828.
2. Betteridge DJ. Long-term risk reduction: Who needs treatment? Diabetes Res. Clin. Pract. 2005;68S2:S15-S22.
3. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 2004;18:805-815.
4. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J. Am. Coll. Cardiol. 2005;46:1425-1433.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial. Lancet. 2003;360:2005-2016.
6. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet 2004;364:685-696.
7. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler. Thromb. Vasc. Biol. 2002;22:1452-1458.
8. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:64-70.
9. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935.
10. Reape TJ, Groot PHE. Chemokines and atherosclerosis. Atherosclerosis. 1999;147:213-225.
11. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: Enhanced biological insights. Atherosclerosis. 2002;160:91-102.
12. Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: Molecular regulation and possible role in human disease. J. Interferon. Cytokine. Res. 1999;19:91-104.
13. Rovin BH, Yoshimura T, Tan L. Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J. Immunol. 1992;148:2148-2153.
14. Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, et al. Production and cytokinemediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int. 1995;48:1477-1486.
15. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, et al. RANTES and MCP-1 play an important role in the inflammatory phase of crescentic nephritis but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 1997;185:1371-1380.
16. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshitomo K, Shimizu M, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000;58:1492-1499.
17. Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J. Diabetes Complications 2003;17:11-15.
18. Morii T, Fujita H, Narita T, Koshimura J, Shimotomai T, Fujishima H, et al. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal disease. Ren. Fail. 2003;25:439-444.
19. Koshimura J, Narita T, Sasaki H, Hosoba M, Yoshioka N, Shimotomai T, et al. Urinary excretion of transferrin and orosomucoid are increased after acute protein loading in healthy subjects. Nephron Clin. Pract. 2005;100:c33-c37.
20. Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int. 1993;43:218-225.
21. Coritsidis G, Rifici V, Gupta S, Rie J, Shan ZH, Neugarten J, et al. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int. 1991;39:858-866.
22. Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D. Interactions of LDL and modified LDL with mesangial cells and matrix. Kidney Int. 1992;41:1161-1169.
23. Sorof J, Berne C, Siewert-Delle A, Jorgensen L, Sager P. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2006;72:81-87.
24. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J. Am. Soc. Nephrol. 2003;14:1605-1613.
25. Feng L, Matsumoto C, Schwartz A, Schmidt AM, Stern DM, Pile-Spellman J. Chronic vascular inflammation in patients with type 2 diabetes. Diabetes Care 2005;28:379-384.
26. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690-695.
27. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto J de P, Morrow DA, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J. Am. Coll. Cardiol. 2004;44:1812-1818.